Want to see GB:SBTX full AI Analyst Report?
Total Valuation
SkinBioTherapeutics has a market cap or net worth of £27.21M. The enterprise value is 28.27M .
Market Cap£27.21M
Enterprise Value28.27M
Share Statistics
SkinBioTherapeutics has 259,168,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding259,168,670
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
SkinBioTherapeutics’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -7.48%.
Return on Equity (ROE)-0.07
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-7.48%
Return on Capital Employed (ROCE)-0.08
Revenue Per Employee309.21K
Profits Per Employee-47.67K
Employee Count15
Asset Turnover0.38
Inventory Turnover2.42
Valuation Ratios
The current PE Ratio of SkinBioTherapeutics is ―. SkinBioTherapeutics’s PEG ratio is 0.68.
PE Ratio―
PS Ratio8.25
PB Ratio4.06
Price to Fair Value4.06
Price to FCF-29.35
Price to Operating Cash Flow-13.42
PEG Ratio0.68
Income Statement
In the last 12 months, SkinBioTherapeutics had revenue of 4.64M and earned -696.25K in profits. Earnings per share was 0.00.
Revenue4.64M
Gross Profit2.71M
Operating Income-826.79K
Pretax Income-715.12K
Net Income-696.25K
EBITDA-196.54K
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -2.02M and capital expenditures -25.24K, giving a free cash flow of -2.05M billion.
Operating Cash Flow-2.02M
Free Cash Flow-2.05M
Free Cash Flow per Share>-0.01
Dividends & Yields
SkinBioTherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.02
52-Week Price Change-36.36%
50-Day Moving Average9.89
200-Day Moving Average13.19
Relative Strength Index (RSI)51.03
Average Volume (3m)673.17K
Important Dates
SkinBioTherapeutics upcoming earnings date is Dec 2, 2026, TBA (Confirmed).
Last Earnings DateJun 8, 2026
Next Earnings DateDec 2, 2026
Ex-Dividend Date―
Financial Position
SkinBioTherapeutics as a current ratio of 4.84, with Debt / Equity ratio of 11.77%
Current Ratio4.84
Quick Ratio4.29
Debt to Market Cap0.02
Net Debt to EBITDA19.26
Interest Coverage Ratio-8.99
Taxes
In the past 12 months, SkinBioTherapeutics has paid -18.86K in taxes.
Income Tax-18.86K
Effective Tax Rate0.03
Enterprise Valuation
SkinBioTherapeutics EV to EBITDA ratio is -175.51, with an EV/FCF ratio of -26.45.
EV to Sales7.44
EV to EBITDA-175.51
EV to Free Cash Flow-26.45
EV to Operating Cash Flow-26.57
Balance Sheet
SkinBioTherapeutics has £3.12M in cash and marketable securities with £939.16K in debt, giving a net cash position of £2.19M billion.
Cash & Marketable Securities£3.12M
Total Debt£939.16K
Net Cash£2.19M
Net Cash Per Share<£0.01
Tangible Book Value Per Share£0.02
Margins
Gross margin is 56.51%, with operating margin of -17.83%, and net profit margin of -15.01%.
Gross Margin56.51%
Operating Margin-17.83%
Pretax Margin-15.42%
Net Profit Margin-15.01%
EBITDA Margin-4.24%
EBIT Margin-13.43%
Analyst Forecast
The average price target for SkinBioTherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast95.16%
EPS Growth Forecast85.60%